Consortium Partners

Q-PLAN is an innovation and management consulting company based in Thessaloniki, Greece. It focuses on design, management and implementation of Research and Innovation projects as well as studies; support of private or public organisations of different types and sizes to (re)design, implement, audit and accredit/ certify their management systems and processes; and support services for businesses to make the most out of available funding and financing opportunities. Q-PLAN has been involved in over 55 EU-funded projects and policy studies.

The Institut Català de Nanociència i Nanotecnologia, acronym ICN2, is a non-profit international research institute located close to Barcelona (Catalonia, Spain). It is devoted to the generation of knowledge, materials and devices in the broad fields of ICT, health, energy and the environment.

The expertise of the ICN2 lies at the nanoscale, where new properties, interactions and ways to exploit them in everyday life are being discovered. Among its goals is to bring together scientists from diverse backgrounds in the pursuit of better science, better training and better outreach to society, while also seeking out new ways to engage with local and global industry.

Grapheal realizes flexible bioelectronic sensors, digital by design, minimalistic in components, with capabilities to detect and dose molecular biomarkers & pathogens with mobile technologies. Grapheal integrates the entire design value chain from synthesis of sensing nanomaterials to complete sensor integration with wireless connectivity, embedded data analysis, and software development. Through its original platform, Grapheal provides competitively priced solutions without the need to purchase a dedicated reader, while collecting digital results in a few minutes.

Aristotle University of Thessaloniki (AUTH) (https://www.auth.gr/en) is the largest Higher Education Institution in Greece and one of the largest in Southeastern Europe. It is known as the most interdisciplinary university of the country with a wide range of offered services in basic and applied research, as well as in research on humanities and social sciences. It comprises 10 faculties which consist of 40 schools and 1 single-School Faculty. Its strategic objectives, in the framework of its vision/mission, remain high and consistently oriented to the continuation of its tradition; namely, to be a pioneer institution, standing out among Greek and many foreign Universities on all levels: education, research, culture, connection with society. AUTH is committed to perform high quality research in pioneering topics aiming at quality and excellence promotion. Due to its wide range of scientific actions AUTH can implement research, technological, educational, and training projects at almost all scientific fields.

Novaptech is a biotech company internationally renowned for its expertise in aptamers – synthetic oligonucleotides displaying antibody-like properties. Novaptech carries out R&D projects for its customers worldwide, in the pharma and life sciences areas, for therapeutic and diagnostic applications. It also designs aptamer-based biosensors and tests in the frame of its in-house R&D programs.

In the frame of the EU-funded project 2D-BioPAD, Novaptech will select, characterize, optimize and functionalize aptamers to Alzheimer’s Disease (AD) biomarkers, hence participating in the development of a fast and cost-effective, non-invasive, reliable Point-of-Care (PoC) in-vitro diagnostics (IVD) system for supporting the early diagnosis and progression monitoring of AD directly at primary healthcare settings.

UEF is the most multidisciplinary university in Finland, established in 2010 following the merger of University of Joensuu (est. 1969) and University of Kuopio (est. 1972). The high standards of interdisciplinary research and education respond to global challenges and build a sustainable future. UEF strategic research is focused on four profile areas: ageing, lifestyles and health; environmental change and sustainable use of natural resources; cultural encounters, mobilities and borders; and diversifying learning and interaction. The 2D-BioPAD UEF team reflects the close collaboration between the Brain Research Unit at the School of Medicine, Faculty of Health Sciences, and the Neuro-Ethics and Law Research Group at the School of Law, Faculty of Social Sciences and Business Studies.

The Greek Association of Alzheimer’s Disease and Related Disorders (Alzheimer Hellas) is a non-profit organization that was founded in 1995, by relatives of patients with Alzheimer’s Disease as well as by doctors of all specialties. Alzheimer Hellas operates two Day Care Centers in Thessaloniki, one in Katerini, a Day center for caregivers, a Home care unit, and an inpatient facility for End-stage Dementia patients. Alzheimer Hellas, since 2000, has organized Pan-Hellenic Interdisciplinary Conferences in addition to informative lectures and seminars.

It participates in Greek, European, and international research projects, Pharmaceuticals, and Nutraceuticals trials. Since 1995, It has been an active member of the International and European Alzheimer’s Associations and participates in every major conference on the field of dementia. 11 Pan-Hellenic Inter-Scientific Alzheimer Conferences have been carried out until now along with the 13th European Alzheimer Conference in Thessaloniki and the 25th International Conference.

Evnia was founded in 2015 in Copenhagen with the vision to become the missing link between manufacturers, regulators and investors for the time-effective commercialization of innovative medical devices and in-vitro diagnostics. Headquartered in Denmark, the company currently has offices in the UK, Greece and Italy and is servicing life-science clients globally. It has been certified under ISO 9001:2015 as a clinical and regulatory affairs consultancy within the life science industry.

Evnia offers a cluster of services from the early stages of a medical device’s lifecycle until its post-market adulthood. We support healthcare innovation and patient safety by providing services in the fields of

• Due Diligence
• Regulatory Strategy
• Clinical Development Strategy
• Post-Market Surveillance
• Real World Evidence
• Market Access and Reimbursement
• EU and UK Representation Services (AR & UKCA)

Our full-value-chain services are supported by a cross-functional team of medical writers, doctors, usability engineers, biostatisticians, biocompatibility experts and regulatory affairs executives.

The Central Institute of Mental Health stands at the forefront of global research and pioneering treatments across various domains of mental health, including psychiatry, psychotherapy, child and adolescent psychiatry, psychosomatic medicine, and addiction medicine. With four clinics strategically located in Mannheim, they ensure comprehensive psychiatric care for individuals of all age groups. Renowned as one of the premier institutions in psychiatric research in Europe, their commitment is evident through a dedicated team of over 1,400 employees. As they consistently expand their capacities, the institute remains at the forefront of innovation, creating new avenues for groundbreaking research and delivering compassionate treatment to those in need.

CeADAR, as Ireland’s national centre for AI, offers a comprehensive service in all aspects of innovation and applied R&D in AI, Machine Learning and Data Analytics. CeADAR has no-charge proofs-of-concept, market-ready solutions, and supports companies in finding funding and investment. We also deliver training and upskilling courses for beginners to advanced practitioners and for business decision-makers. Our ecosystem of hundreds of companies provides access to a vibrant network of multinational companies, SMEs and startups in Ireland and throughout Europe.

CeADAR is a creative AI powerhouse and Ireland’s only European Digital Innovation Hub (EDIH) in AI focused on delivering value and sustained competitive advantage through accelerated research, development and deployment of AI and data analytics technology and innovation into business.